Vaccinex, INC 8-K filings

Bala S. Manian resigned from the Vaccinex, Inc. Board of Directors on March 18, 2025, with his departure not stemming from any disagreements with the company.

Vaccinex, Inc. has announced its intention to delist its common stock from the Nasdaq Stock Market following a suspension of trading and a determination by the Nasdaq Hearings Panel.

Vaccinex, Inc. will be delisted from the Nasdaq Stock Market due to not meeting the minimum stockholders' equity requirement and will transition to the OTC Markets Group.

Vaccinex, Inc. has successfully completed a private placement, raising approximately $2.15 million through the issuance of common stock and pre-funded warrants.

Vaccinex, Inc. has received a delisting notice from Nasdaq after failing to meet minimum equity requirements, and intends to appeal the decision.

Vaccinex, Inc. has raised approximately $6.2 million through the exercise of existing warrants and the issuance of new warrants in a private placement.

Chrystyna Bedrij Stecyk has resigned from the Vaccinex board of directors, effective immediately, with no disagreements cited as the reason.

Vaccinex Inc. has called for the cancellation of outstanding warrants after reporting a statistically significant increase in FDG-PET signal in its Alzheimer's trial, potentially leading to further financing activities.

Vaccinex reports positive results from its SIGNAL-AD Phase 1b/2 trial, showing pepinemab slowed cognitive decline in patients with mild cognitive impairment due to Alzheimer's disease and plans to pursue a development partnership.

Vaccinex reports positive results from its early-stage SIGNAL-AD clinical trial, showing pepinemab is well-tolerated and demonstrates a statistically significant increase in brain metabolic activity in patients with Mild Cognitive Impairment due to Alzheimer's Disease.

Vaccinex has announced the completion of the last patient visit in its Phase 1b/2 SIGNAL-AD study of pepinemab for Alzheimer's disease, with key results expected in July.

Vaccinex, Inc. held its annual stockholders meeting on May 9, 2024, where key proposals including the election of directors and executive compensation were voted on.

Vaccinex, Inc. has received a notice from Nasdaq for not meeting the minimum stockholders' equity requirement for continued listing.

Vaccinex, Inc. has successfully raised approximately $4.5 million through a registered direct offering and concurrent private placements, including the sale of preferred stock.

Vaccinex, Inc. has successfully closed a registered direct offering, raising approximately $1.5 million through the sale of common stock and warrants.

Vaccinex, Inc. has entered into a securities purchase agreement to raise approximately $1.5 million through a public offering and concurrent private placement.

Vaccinex Inc. has announced the retirement of its Chief Financial Officer, Scott E. Royer, effective March 14, 2024, and the appointment of Jill Sanchez as Interim CFO.

Vaccinex has announced eight new agreements for its ActivMAb antibody discovery platform, signaling increased interest in its technology for challenging drug targets.

Vaccinex has enacted a 1-for-14 reverse stock split of its common stock, effective February 19, 2024, to meet Nasdaq's minimum bid price requirement.

Vaccinex stockholders have approved a reverse stock split of its common stock at a special meeting held on February 8, 2024.

Vaccinex, Inc. filed an amendment to its original 8-K report to correct an error in the form of a common warrant that was previously filed.

Vaccinex, Inc. has entered into a securities purchase agreement to issue pre-funded and common stock purchase warrants, along with shares of common stock, in a private placement expected to generate approximately $3.7 million in gross proceeds.